Berberine is a plant-derived isoquinoline alkaloid studied across tumor metabolism, apoptosis, invasion, inflammatory signaling, the microbiome and treatment response.
Share your diagnosis, current treatment and the questions you want the clinical team to consider.
Tell us what you are facing and what you hope to understand. The team will follow up personally.
Sunridge evaluates berberine in the context of the cancer type, medications, glucose regulation, digestive tolerance and the larger integrative plan. The research library below brings the positive findings together by cancer type.
Berberine increased TRAIL-related apoptosis and strengthened anti-DR5 activity against primary tumor growth and lung metastasis in the reported breast-cancer model.
A multicenter double-blind randomized trial after polypectomy reported recurrent adenomas in 36% of the berberine group versus 47% with placebo.
Mechanistic follow-up connected berberine-associated adenoma findings with Veillonella parvula and B-cell regulation.
Berberine changed the tumor-promoting activity of colon-cancer-derived exosomes and reduced recipient-cell viability, migration and invasion.
Berberine inhibited gastric-cancer development and progression through IL-6 and JAK2/STAT3-associated signaling in cell and tumor models.
Berberine sensitized liver-cancer cells to sorafenib through ferroptosis- and p53-associated mechanisms in the reported study.
A review organized berberine-associated apoptotic signaling in breast, lung and liver cancers and discussed strategies to improve bioavailability.
A comprehensive review summarized reported effects involving apoptosis, cell cycle, autophagy, invasion and metastasis across numerous cancer types.
This review describes berberine as a multitarget natural compound studied across apoptosis, autophagy, cell-cycle arrest, invasion and metastasis.
A recent update reviews berberine research in ovarian, breast, lung, gastric, liver, colorectal, cervical and prostate cancers.
Berberine reduced viability, colony formation and migration and shifted EMT-associated markers in osteosarcoma cells.
In osteosarcoma models, berberine reduced proliferation, migration and invasion and inhibited tumor growth through MAPK/JNK-associated signaling.
Our Patient Care Team can help you begin a conversation about your diagnosis, current oncology plan, goals, medicines and integrative options used at Sunridge.
14200 N Northsight Blvd #160
Scottsdale, Arizona 85260
Monday–Friday: 9:00 AM–5:00 PM
Saturday: 9:00 AM–12:00 PM
Tell us what you are facing. There is no charge to speak with our Patient Care Team, understand how Sunridge works and determine whether a physician consultation may be an appropriate next step.
This introductory call is not a medical consultation and does not establish a physician-patient relationship.
